{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02204",
      "entity_text" : "anti-PD-1 mAbs pembrolizumab",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:446013",
      "entity_text" : "FDA",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "As a consequence, the FDA accelerated the approval of anti-PD-1 mAbs pembrolizumab and nivolumab, and anti-PD-L1 mAbs durvalumab, atezolizumab and avelumab, which have since become available as standard-of-care for several cancer types.",
  "reading_complete" : "2020-08-02T09:41:06Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T09:39:06Z",
  "trigger" : "accelerated",
  "evidence" : [ "FDA accelerated the approval of anti-PD-1 mAbs pembrolizumab" ],
  "pmc_id" : "6037030",
  "score" : 0
}